Posted by Michael Wonder on 21 Mar 2025
US FDA approves Tremfya (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn’s disease
20 March 2025 - Supported by data from the GALAXI study, Tremfya is the only IL-23 inhibitor to show superiority versus Stelara in all pooled endoscopic endpoints within a double-blinded registrational trial.
Johnson & Johnson today announced that the US FDA has approved Tremfya (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for the treatment of adults with moderately to severely active Crohn’s disease, a chronic inflammatory condition of the gastro-intestinal tract.
